Organogenesis Holdings (ORGO) Common Equity (2015 - 2026)

Organogenesis Holdings' Common Equity history runs 12 years deep, the most recent figure standing at $244.6 million for Q1 2026.

• In Q1 2026, Common Equity rose 0.68% year-over-year to $244.6 million; the TTM figure through Mar 2026 stood at $244.6 million (up 0.68% YoY), while the FY2025 annual figure was $300.1 million, up 14.16% from the prior year.
• Common Equity was $244.6 million for Q1 2026 at Organogenesis Holdings, down from $300.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $300.1 million in Q4 2025 to a low of $233.2 million in Q2 2025.
• Historically, Common Equity has averaged $262.8 million across 5 years, with a median of $263.5 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Common Equity surged 57.84% in 2022, then declined 12.63% in 2025.
• A 5-year view of Common Equity shows it stood at $265.7 million in 2022, then advanced by 4.89% to $278.7 million in 2023, then dropped by 5.66% to $262.9 million in 2024, then rose by 14.16% to $300.1 million in 2025, then fell by 18.52% to $244.6 million in 2026.
• The last three Common Equity figures came in at $244.6 million (Q1 2026), $300.1 million (Q4 2025), and $255.1 million (Q3 2025), per Business Quant data.